# ProfoundBio US Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/profoundbio-us

- Industry: Biotechnology
- Headquarters: Woodinville, US
- Total disclosed funding: $237M
- Latest round: Series B (Feb 13, 2024)
- Investors on record: 18

## About

Founded in 2018 and based in Washington, US, ProfoundBio US Co., operates as a medical company for oncology biotherapeutics firms that are developing innovative antibody-based medicines with the potential to cure cancer patients. In May 2024, Genmab A/S acquired ProfoundBio US Co. from Ally Bridge Group, Chang'an Capital, Gaorong Ventures, Janus Henderson Investors, K2VC, LifeSci Venture Partners, Lilly Asia Ventures, Logos Capital, LYFE Capital, Medicxi Ventures, Octagon Capital, OrbiMed Advisors, Oriza Holdings, Piper Heartland Healthcare Capital, Sequoia Capital Global Equities, Sierra Technologies, Inc., Surveyor Capital, and T. Rowe Price, for USD 1.8 billion. The company's product pipeline primarily consists of antibody-coupled drugs (ADCs) and other antibody-based therapeutic programs. In addition, it develops novel targeted drugs including PRO1184, an ADC drug targeting folate receptor alpha (FRa), and PRO1160, an ADC drug covering hematologic and solid tumor indications targeting CD70.

## Funding rounds

- Series B, Feb 13, 2024, $112M — OrbiMed Advisors, Lilly Asia Ventures, Surveyor Capital, Ally Bridge Group, Janus Henderson Investors, LYFE Capital, Medicxi, LifeSci Partners, T Rowe Price Advisory Services, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, Sierra Technologies, Inc.
- Series A, Jun 2, 2022, $70M — Hong Shan, Lilly Asia Ventures, Oriza Holdings, Chang'an Capital, K2VC, LYFE Capital
- Series A, Jul 12, 2021, $55M — Hong Shan, Lilly Asia Ventures, Chang'an Capital, Gaorong Ventures, K2VC, LYFE Capital

## Investors

- Hong Shan — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- LYFE Capital — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Surveyor Capital — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B
- Janus Henderson Investors — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- T Rowe Price Advisory Services — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Octagon Capital — Series B
- Piper Heartland Healthcare Capital — Series B
- Sierra Technologies, Inc. — Series B